{
    "id": 24235,
    "fullName": "GAB2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "GAB2 over exp indicates an over expression of the Gab2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9846,
        "geneSymbol": "GAB2",
        "terms": [
            "GAB2"
        ]
    },
    "variant": "over exp",
    "createDate": "07/12/2016",
    "updateDate": "11/23/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7281,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Gleevec (imatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052)",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7284,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Iclusig (ponatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7283,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Tasigna (nilotinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Sprycel (dasatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7286,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 with over expression of Gab2 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7285,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 with over expression of Gab2 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24965,
            "profileName": "GAB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24966,
            "profileName": "BCR - ABL1 GAB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}